Communiqués OmniAb, Inc.

Actions

OABI

US68218J1034

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
3,77 ^USD	-2,84 %		-7,14 %	-38,90 %

29/05	Un initié d'Omniab a acheté des actions pour une valeur de 1 059 840 $, selon un récent dépôt auprès de la SEC	MT
09/05	OmniAb, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

OmniAb : Submission of Matters to a Vote of Security Holders Form 8 K	21/06	PU
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology	03/06	BU
OmniAb to Participate in the Jefferies Global Healthcare Conference	20/05	BU
OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit	15/05	BU
OmniAb : May 2024 Corporate Overview	10/05	PU
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights	09/05	BU
OmniAb to Participate in Five Investor Conferences in May	01/05	BU
OmniAb to Report First Quarter 2024 Financial Results on May 9	22/04	BU
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics	16/04	AQ
OmniAb : March 2024 Corporate Overview	26/03	PU
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	20/03	BU
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20	26/02	BU
OmniAb to Participate in Two Investor Conferences in March	20/02	BU
OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering and Therapeutics Conference	15/12	AQ
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference	14/12	BU
OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual Event	09/11	BU
OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights	09/11	BU
OmniAb to Participate in Two Investor Conferences in November	02/11	BU
OmniAb Appoints Steve Love to its Board of Directors	01/11	BU
OmniAb Announces Agenda for its Research & Technology Virtual Event	31/10/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués OmniAb, Inc.

Actions

OABI

US68218J1034

Communiqués

Filtres